Protalix Q1 2026 net income $18.3 million on $25 million Chiesi milestone
Protalix reported first-quarter 2026 total revenue of $33.8 million, up from $10.1 million a year earlier, and net income of $18.3 million, compared with a net loss of $3.6 million in the prior-year quarter. The increase was driven mainly by a $25.0 million milestone from partner Chiesi, and the company reaffirmed its 2026 total revenue guidance of $78.0 million to $83.0 million, which includes that milestone.
Key points
- Total revenue was $33.8 million for the quarter ended March 31, 2026, versus $10.1 million a year earlier.
- Net income was $18.3 million, or $0.23 per share basic and $0.22 diluted, versus a net loss of $3.6 million, or $(0.05) per share, in Q1 2025.
- Revenue from selling goods fell to $7.4 million from $10.0 million, mainly due to a timing shift in Pfizer's Elelyso purchases.
- The company reaffirmed 2026 total revenue guidance of $78.0 million to $83.0 million and reported cash and short-term deposits of $51.1 million as of March 31, 2026.
The filing
Written by AI on Nov 9, 2026, 8:29 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 13, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.